{
    "nctId": "NCT00485979",
    "briefTitle": "Treatment of Larotaxel/Docetaxel, +/- Trastuzumab, After Anthracycline-cyclophosphamide in Breast Cancer Patients",
    "officialTitle": "A Randomized, Open-label, Multi-center Study of Larotaxel at 90mg/m2 or Docetaxel Every 3 Weeks, Alone or in Combination With Trastuzumab According to Her2neu Status, Administered After a Combination of Anthracycline and Cyclophosphamide as Pre-operative Therapy in Patients With High Risk Localized Breast Cancer.",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Neoplasms",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 330,
    "primaryOutcomeMeasure": "Pathological response will be assessed according to Chevallier criteria for patients who underwent surgery.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically proven invasive breast adenocarcinoma\n* Localized breast cancer: stage II and III\n* Tumors clinically palpable and ineligible for breast conservative surgery: unifocal tumor with diameter \u2265 3cm (clinical examination) or central unifocal tumor, or whose characteristics make pre-operative chemotherapy mandatory due to high risk factors (i.e. ipsilateral lymph nodes involvement, rapid growth rate)\n* After 30 June 2008, known status for Her2neu by immunohistochemistry (IHC) or by fluorescent in situ hybridization (FISH)\n\nExclusion Criteria:\n\n* Bilateral and inflammatory breast cancer\n* Abnormal Left Ventricular Ejection Fraction\n* Distant metastases or locoregional relapse\n* Inadequate organ functions\n\nThe above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}